ABCL News & Events

Latest data shows the largest indicative borrow rate increases among liquid option names include: T-REX 2X Long BMNR Daily Target ETF (BMNU) 26.92% +16.53, Eagle Nuclear Energy Corp (NUCL) 144.63% +3.65, Almonty Industries Inc. Common Shares (ALM) 5.78% +1.45, T-REX 2X LONG MSTR DAILY TARGET (MSTU) 14.83% +1.28, YIELDMAX MSTR OPTION INCOME STRATEGY ETF (MSTY) 9.42% +0.97, Nexa Resources (NEXA) 25.25% +0.93, Innovatum Global N.V. (NKLR) 15.60% +0.77, Tidal Trust II (IRE) 22.07% +0.70, AbCellera Biologics (ABCL) 4.65% +0.48, and ProShares UltraShort Lehman 20 plus Year Treasury (TBT) 8.29% +0.43.

Reports Q1 revenue $8.3M, consensus $5.8M. "We are excited to share interim Phase 1 data that show ABCL635 achieved robust NK3R target engagement at doses that were well-tolerated in healthy volunteers and a pharmacokinetic profile that may support a once monthly dosing regimen. We look forward to the efficacy readout from the Phase 2 data in Q3, which we believe will be highly de-risking for the program," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "Through 2026 we are focused on delivering data readouts for our clinical programs, advancing ABCL688 and ABCL386 into IND-enabling studies, and selecting at least one additional development candidate. We continue to maintain our strong cash position, ending the quarter with approximately $655 million dollars in available liquidity to execute on our strategy."